Pre-treatment mpMRI accuracy and prognostic value in intermediate risk localized prostate cancer

被引：0
|
作者：
Buchser, D. [1 ]
Gomez-Iturriaga, A. [1 ]
Casquero, F. [1 ]
Urresola, A. [2 ]
Ezquerro, A. [2 ]
Cacicedo, J. [1 ]
San Miguel, I. [1 ]
Suarez, F. [1 ]
Bilbao, P. [1 ]
机构：
[1] Hosp Univ Cruces, Radiat Oncol, Baracaldo, Spain
[2] Hosp Univ Cruces, Radiol, Baracaldo, Spain
来源：
RADIOTHERAPY AND ONCOLOGY | 2018年 / 127卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1612
引用
收藏
页码：S867 / S868
页数：2
相关论文
共 50 条
  • [21] PROGNOSTIC VALUE OF THE PERCENTAGE OF FREE PSA IN THE LOCALIZED PROSTATE CANCER
    Filella, X.
    Alcover, J.
    Molina, R.
    Auge, J. M.
    Corral, J.
    Escudero, J. M.
    TUMOR BIOLOGY, 2010, 31 : S117 - S117
  • [22] Prognostic gene signature for intermediate risk prostate cancer
    Li, Brian
    Hallet, Robin
    Wu, Ying
    Pong, Greg
    Hassell, John
    Hotte, Sebastien
    Levine, Mark
    Lukka, Himansu
    Bane, Anita
    CANCER RESEARCH, 2015, 75
  • [23] Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer
    Matsubara, Sho
    Mabuchi, Seiji
    Takeda, Yoshinori
    Kawahara, Naoki
    Kobayashi, Hiroshi
    PLOS ONE, 2021, 16 (05):
  • [24] Comprehensive analysis of the prognostic value of pre-treatment nutritional indicators in elderly rectal cancer patients
    Qiu, Jianjian
    Yu, Yilin
    Wang, Zhiping
    Hong, Liang
    Shao, Lingdong
    Wu, Junxin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [25] Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance
    Sherer, Michael, V
    Leonard, Austin J.
    Nelson, Tyler J.
    Guram, Kripa
    De Moraes, Gustavo Rodrigues
    Javier-Desloges, Juan
    Kane, Christopher
    McKay, Rana R.
    Rose, Brent S.
    Bagrodia, Aditya
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 50 : 61 - 67
  • [26] Localized intermediate- to high-risk prostate cancer
    Tritschler, S.
    Ganswindt, U.
    Stief, C. G.
    UROLOGE, 2016, 55 (03): : 318 - +
  • [27] Intermediate risk localized prostate cancer: Which radiotherapeutic approach?
    Gondi, V
    Deutsch, I
    Vecchio, D
    Goluboff, E
    Ennis, RD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 448S - 448S
  • [28] Prognostic Value of the Different Pre-Treatment Biomarkers for Patients with Neuroendocrine Tumors
    Grigorescu, R. R.
    Croitoru, A.
    Stanel, I
    Gheorghe, C.
    Grama, I
    Dinu, I
    Buica, F.
    Luca, I
    NEUROENDOCRINOLOGY, 2018, 106 : 154 - 154
  • [29] TREATMENT OF LOCALIZED HIGH RISK PROSTATE CANCER
    Tombal, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 22 - 23
  • [30] Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy
    Magrowski, Lukasz
    Masri, Oliwia
    Ciepal, Jakub
    Depowska, Gabriela
    Nowicka, Zuzanna
    Stando, Rafal
    Chimiak, Krystyna
    Bylica, Gabriela
    Czapla, Barbara
    Masri, Malgorzata
    Cichur, Franciszek
    Jablonska, Iwona
    Gmerek, Marta
    Wojcieszek, Piotr
    Krzysztofiak, Tomasz
    Sadowski, Jacek
    Suwinski, Rafal
    Rajwa, Pawel
    Moll, Matthias
    Goldner, Gregor
    Majewski, Wojciech
    Miszczyk, Marcin
    BIOMEDICINES, 2022, 10 (10)
12345